AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
Acquiring Company
Merck KGaA Darmstadt Germany
Acquired Company
Bio-Techne Corporation
Description
On September 23, 2026, Bio-Techne Corporation held a special meeting to consider the merger agreement with Merck KGaA. The agreement allows Merck's subsidiary, EMD Holdings NewCo, Inc., to merge with Bio-Techne, making Bio-Techne a wholly-owned subsidiary of Merck. The transaction is set to expand Merck's presence in the life sciences sector.
Fundz sees it the moment Merck KGaA Darmstadt Germany makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Bio-Techne Corporation?
Bio-Techne Corporation was acquired by Merck KGaA Darmstadt Germany, based in Hesse. The deal was reported on September 23, 2026. Merck KGaA is a leading science and technology company known for its innovative solutions in healthcare, life sciences, and performance materials. Merck KGaA Darmstadt Germany is privately held and operates in Manufacturing.
When did Merck KGaA Darmstadt Germany acquire Bio-Techne Corporation?
Merck KGaA Darmstadt Germany's acquisition of Bio-Techne Corporation was reported on September 23, 2026. On September 23, 2026, Bio-Techne Corporation held a special meeting to consider the merger agreement with Merck KGaA. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Bio-Techne Corporation do?
Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. It is publicly traded (TECH), operating in Manufacturing, and is based in Minneapolis.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
5 screens from a live account. No signup.